Quisqualamine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Quisqualamine is the α-decarboxylated analogue of the glutamate receptor agonist and neurotoxin quisqualic acid and an analogue of the neurotransmitter γ-aminobutyric acid (GABA).[1][2]
- None
| Clinical data | |
|---|---|
| Drug class | GABAA receptor agonist; Glycine receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C4H7N3O3 |
| Molar mass | 145.118 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
α-Decarboxylation of excitatory amino acids can produce derivatives with inhibitory effects.[2] Relatedly, unlike quisqualic acid, quisqualamine has central depressant and neuroprotective effects, and appears to act predominantly as an agonist of the GABAA receptor and to a lesser extent as an agonist of the glycine receptor.[1][2][3] Its actions are inhibited by GABAA receptor antagonists like bicuculline and picrotoxin and by the glycine receptor antagonist strychnine in vitro.[1][2][3]
The NMDA receptor antagonists magnesium and DL-AP5, the AMPA and kainate receptor antagonist CNQX, and the GABAB receptor antagonist 2-hydroxysaclofen all do not affect quisqualamine's actions in vitro.[2] As such, the drug does not appear to interact with the ionotropic glutamate receptors or GABAB receptor.[2]